Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy

被引:18
作者
Lee, LW
McBain, CA
Swindell, R
Wylie, JP
Cowan, RA
Logue, JP [1 ]
机构
[1] Christie Hosp, Dept Clin Oncol, Manchester M20 4BX, Lancs, England
[2] Christie Hosp, Dept Med Stat, Manchester, Lancs, England
关键词
prostate cancer; radical prostatectomy; radiotherapy; salvage;
D O I
10.1016/j.clon.2004.07.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To review the outcome of men receiving hypofractionated salvage radiotherapy for rising prostate-specific antigen (PSA) after radical prostatectomy. Materials and methods: A. retrospective analysis of 61 men referred for salvage radiotherapy for biochemical relapse after radical prostatectorny was conducted. Twenty-four men receiving hormonal therapy or with follow-up of less than 12 months were excluded. Thirty-seven men were identified, median age 64 years, median preoperative PSA 11 ng/ml (5.6-60 ng/ml), Gleason scores < 7: 70%, Gleason scores greater than or equal to 7: 30%. Twenty-seven men had positive surgical resection margins, eight had seminal-vesicle involvement and one had lymph-node involvement. Diagnosis of failure after radical prostatectomy was made on rising PSA in all cases; 19 men also had positive magnetic resonance imaging, 11 abnormal digital rectal examination and nine positive biopsy. Radiotherapy was delivered conformally to the prostatic fossa, 50-52.5 Gy in 20 fractions over 4 weeks. Date of failure after radiotherapy was defined by the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria or as date of commencement of hormonal therapy for rising PSA. Results: Median time front radical prostatectorny to radiotherapy was 30.6 months (8-68 months); median pre-radiotherapy PSA was 2.9 ng/ml (0.5-11.4 ng/ml). PSA response after radiotherapy was seen in 33 out of 37 (89%) patients. At median follow-up of 36 months (20-85 months), 28 out of 37 remained disease-free. Thirteen more patients have had two consecutive PSA rises. Actuarial 3-year disease-free survival is 74%. No patient has developed metastases or died of prostate cancer. Pre-radiotherapy PSA less than 2 ng/ml predicted disease-free survival (P = 0.027). No acute toxicity greater than Radiation Therapy Oncology Group (RTOG) G2 was observed. Conclusions: Salvage radiotherapy after radical prostatectomy achieved durable biochemical control in most patients. Outcome is improved if radiotherapy is delivered when PSA is less than 2 ng/ml. A policy of close monitoring after radical prostatectomy with early referral for salvage radiotherapy is advocated. (C) 2004 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:517 / 522
页数:6
相关论文
共 50 条
[21]   Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen [J].
Anscher, MS .
INTERNATIONAL JOURNAL OF CANCER, 2001, 96 (02) :91-93
[22]   The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer [J].
Bartkowiak, Detlef ;
Siegmann, Alessandra ;
Boehmer, Dirk ;
Budach, Volker ;
Wiegel, Thomas .
BJU INTERNATIONAL, 2019, 124 (05) :785-791
[23]   Continuous prostate-specific antigen rise despite salvage radiotherapy following radical prostatectomy: Pattern of clinical relapse and predictive factors [J].
Nieder, Carsten ;
Marienhagen, Kirsten ;
Kristensen, Roy M. ;
Sorbye, Torbjorn ;
Hoem, Lars .
ONCOLOGY LETTERS, 2016, 11 (02) :1138-1142
[24]   Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy [J].
Blas, Leandro ;
Shiota, Masaki ;
Tanegashima, Tokiyoshi ;
Tsukahara, Shigehiro ;
Ueda, Shohei ;
Mutaguchi, Jun ;
Goto, Shunsuke ;
Kobayashi, Satoshi ;
Matsumoto, Takashi ;
Inokuchi, Junichi ;
Eto, Masatoshi .
INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (04) :404-408
[25]   Elimination kinetics of prostate-specific antigen as predictor of prognosis after radical prostatectomy [J].
Hamm, M ;
Semjonow, A ;
Oberpenning, F ;
Mandt, S ;
Rathert, P .
AKTUELLE UROLOGIE, 1996, 27 (06) :385-389
[26]   Salvage radical prostatectomy after failure of radiotherapy for localized prostate cancer [J].
Rigaud, J ;
Tiguert, R ;
Fradet, Y ;
Bouchot, O .
PROGRES EN UROLOGIE, 2002, 12 (06) :1179-1187
[27]   Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients [J].
Gandaglia, Giorgio ;
Briganti, Alberto ;
Clarke, Noel ;
Karnes, R. Jeffrey ;
Graefen, Markus ;
Ost, Piet ;
Zietman, Anthony Laurence ;
Roach, Mack, III .
EUROPEAN UROLOGY, 2017, 72 (05) :689-709
[28]   Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How? [J].
Fossati, Nicola ;
Cozzarini, Cesare ;
Fiorino, Claudio ;
Gandaglia, Giorgio ;
Montorsi, Francesco ;
Briganti, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) :469-+
[29]   Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery [J].
Takuya Aizawa ;
Toshiya Maebayashi ;
Naoya Ishibashi ;
Masakuni Sakaguchi ;
Akahiko Sato ;
Kenya Yamaguchi .
BMC Urology, 23
[30]   Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy [J].
Martini, Alberto ;
Fossati, Nicola ;
Karnes, R. Jeffrey ;
Boorjian, Stephen A. ;
Boeri, Luca ;
Bossi, Alberto ;
Di Muzio, Nadia ;
Cozzarini, Cesare ;
Chiorda, Barbara Noris ;
Gandaglia, Giorgio ;
Robesti, Daniele ;
Bartkowiak, Detlef ;
Boehmer, Dirk ;
Shariat, Shahrokh F. ;
Goldner, Gregor ;
Battaglia, Antonino ;
Joniau, Steven ;
Berghen, Charlien ;
De Meerleer, Gert ;
Fonteyne, Valerie ;
Ost, Piet ;
Van Poppel, Hein ;
Montorsi, Francesco ;
Wiegel, Thomas ;
Briganti, Alberto .
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (02) :301-304